Glucose-substituted ruthenium complexes [(η6-benzyl-glucose)RuCp*]+Cl−, where Cp* = η5-C5Me5; benzyl-glucose = peracetylated benzyl β-d-glucopyranoside (1), benzyl β-d-glucopyranoside (2), have been prepared and used as efficient antimigration and anti-invasive agents against metastatic breast cancer cells (MDA-MB-231) and cisplatin-resistant ovarian cancer cells (SK-OV-3). In addition, these complexes were found to be essentially non-toxic against non-cancerous human kidney cells (HEK293).